Phio Pharmaceuticals (PHIO) Interest & Investment Income (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Interest & Investment Income came in at $130000.0 in Q2 2026, down 9.09% on a YoY basis from $143000.0 in Q2 2025, and down 19.25% quarter-over-quarter from $161000.0 in Q1 2026.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Interest & Investment Income (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Interest & Investment Income for 11 consecutive years, with $130000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income fell 9.09% year-over-year to $130000.0; the trailing twelve-month figure through Jun 2026 stood at $567000.0 (up 50.8% YoY), and the FY2025 full-year result was $520000.0, up 125.11% from the prior year.
- Interest & Investment Income retreated to $130000.0 in Q2 2026 per PHIO's latest filing, from $161000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $163000.0 in Q4 2025 and bottomed at $42000.0 in Q4 2024.
- Historically, Interest & Investment Income has averaged $117875.0 across 3 years, with a median of $127500.0 in 2025.
- The sharpest annual moves came in 2025 and 2026: Interest & Investment Income soared 288.1% in 2025, then fell 9.09% in 2026.
- Over 3 years, Interest & Investment Income stood at $42000.0 in 2024, then jumped by 288.1% to $163000.0 in 2025, then declined by 20.25% to $130000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $130000.0, $161000.0, and $163000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | 130,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 130,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Dec 31, 2025 | 163,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Jun 30, 2025 | 143,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Dec 31, 2024 | 42,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | -2,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2020 | -3,000.00 |
| Mar 31, 2020 | 5,000.00 |
| Sep 30, 2016 | 4,000.00 |
| Jun 30, 2016 | 4,000.00 |
| Mar 31, 2016 | 7,000.00 |
| Dec 31, 2015 | 6,000.00 |
| Sep 30, 2015 | 8,000.00 |